



Laboratory Services Important Test Announcement

UPDATED POLICY ON EXTRACTED RNA SPECIMENS FOR HEMATOLOGIC CANCER FUSION ANALYSIS

Test Code: [HEMFUSN](#)

Effective immediately unprocessed specimens such as blood and bone marrow aspirates are preferred over processed specimens such as extracted RNA for Hematologic Cancer Fusion Analysis. However, if unprocessed specimens are not available, then the IGM laboratory can accept extracted RNA ***if the specimen meets the below requirements:***

- Extraction of RNA was performed in a CLIA-certified laboratory meeting equivalent requirements as determined by the CAP (College of American Pathologists) and/or the CMS (Centers for Medicare & Medicaid Services).
- Submission of a Flow Cytometry report and/or Pathology report are required to show the diagnosis and disease-involvement of the sample. The sample from which extracted RNA was derived should match the date of collection of the Flow Cytometry and/or Pathology report. For patients with acute leukemias, at least 10% blasts must be present in the report for testing to be performed. Sample acquisition PRIOR to receiving treatment is strongly preferred.

It is no longer required to submit a slide/smear made from the exact specimen from which the RNA was extracted. No internal NCH pathology review will occur prior to fusion testing of the received RNA sample, and the institutional Flow Cytometry and/or Pathology report will be considered as representative of the disease-involvement of the RNA sample submitted for testing.

For additional information or questions about [HEMFUSN](#), please call the IGM Clinical Laboratory at 614-722-5321 and ask to speak with a laboratory genetic counselor.